Stanford spinout Toma Biosciences has created a genomics testing platform for classifying cancerous tumours according to their genetic mutations.
Toma Biosciences, a US-based oncological genomics provider based on Stanford University research, has received more than $3.6m in a series C round backed by the university.
The round also featured VC firm Keiretsu Capital and several of its affiliate angel syndicates, dubbed Keiretsu Forum Chapters, as well as Sayj Global Partners, Paladin Capital, Correlation Ventures, Prolog Ventures, Vital Capital, and unnamed family offices and private investors.
Founded in 2011, Toma Biosciences has developed a genomics testing platform, Signome Tumor Profiling…